Ergoteles LLC Madrigal Pharmaceuticals, Inc. Transaction History

Ergoteles LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$231.06 - $307.08 $1.47 Million - $1.95 Million	6,359 Added 311.87%	8,398 $2.03 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $119,057 - $604,645	2,039 New	2,039 $591,000
Q1 2022 May 13, 2022	SELL	$55.89 - $101.89 $582,820 - $1.06 Million	-10,428 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$72.34 - $95.09 $313,810 - $412,500	4,338 Added 71.23%	10,428 $884,000
Q3 2021 Nov 15, 2021	BUY	$78.35 - $105.02 $477,151 - $639,571	6,090 New	6,090 $486,000

337

22.3M

987K

960K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.77B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.